GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...

Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry

Phase 1
Completed
Conditions
Interventions
First Posted Date
2024-08-29
Last Posted Date
2024-12-10
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
30
Registration Number
NCT06577597
Locations
🇬🇧

GSK Investigational Site, Middlesex, United Kingdom

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants

First Posted Date
2024-08-28
Last Posted Date
2024-12-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
112
Registration Number
NCT06576271
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

First Posted Date
2024-08-27
Last Posted Date
2024-08-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
440
Registration Number
NCT06572384
Locations
🇪🇸

GSK Investigational Site, Sevilla, Spain

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-08-23
Last Posted Date
2024-08-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
120
Registration Number
NCT06567782
Locations
🇬🇧

GSK Investigational Site, Sutton, United Kingdom

A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

First Posted Date
2024-08-13
Last Posted Date
2024-08-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
2600
Registration Number
NCT06551181
Locations
🇬🇧

GSK Investigational Site, Witney, United Kingdom

A Study of GSK5764227 in Participants With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2024-08-13
Last Posted Date
2024-11-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
240
Registration Number
NCT06551142
Locations
🇯🇵

GSK Investigational Site, Tokyo, Japan

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

First Posted Date
2024-08-05
Last Posted Date
2024-12-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
280
Registration Number
NCT06537414
Locations
🇬🇧

GSK Investigational Site, Middlesbrough, United Kingdom

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

First Posted Date
2024-08-02
Last Posted Date
2024-08-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
12000
Registration Number
NCT06534892
Locations
🇬🇧

GSK Investigational Site, Witney, United Kingdom

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

Recruiting
Conditions
Interventions
First Posted Date
2024-07-30
Last Posted Date
2024-11-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
300
Registration Number
NCT06527872
Locations
🇺🇸

GSK Investigational Site, Charlotte, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath